Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/40502 |
Resumo: | Despite the therapeutic options currently available for Heart Failure (HF), this pathology is still responsible for high rates of morbidity and mortality in the population. Faced with these current therapeutic limitations, the development of studies to evaluate the effectiveness of new drugs in HF is justified, among them the sodium-glucose cotransporter type 2 (SGLT2) inhibitors. In this context, the objective of this work is to evaluate the benefits and limitations of SGLT2 inhibitors in the management of HF. The present study is an integrative literature review carried out from the PubMed and VHL databases. Seven randomized clinical studies controlled by placebo were analyzed, from which it was verified that SGLT2 inhibitors presented promising therapeutic effect, with cardioprotective and renoprotective action, in a broad spectrum of HF, reducing the risk of hospitalizations and deaths from causes cardiovascular effects, regardless of the presence or absence of DM2, in addition to being safe and well tolerated. Therefore, the use of SGLT2 inhibitors represents an additional effective and safe therapeutic alternative with the potential to modify the morbidity and mortality of HF. |
id |
UNIFEI_04cd93b40461269b6e12f07010d19437 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/40502 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic optionAvances en la farmacoterapia de la Insuficiencia Cardiaca: los Inhibidores del cotransportador sodio-glucosa tipo 2 (SGLT2) como opción terapéuticaAvanços na farmacoterapia da Insuficiência Cardíaca: os Inibidores do cotransportador sódio-glicose do tipo 2 (SGLT2) como opção terapêuticaInibidores do Transportador 2 de Sódio-GlicoseInsuficiência CardíacaEficácia.Sodium-Glucose Transporter 2 InhibitorsHeart FailureEfficacy.Inhibidores del transportador de sodio-glucosa 2Insuficiencia cardíacaEficacia.Despite the therapeutic options currently available for Heart Failure (HF), this pathology is still responsible for high rates of morbidity and mortality in the population. Faced with these current therapeutic limitations, the development of studies to evaluate the effectiveness of new drugs in HF is justified, among them the sodium-glucose cotransporter type 2 (SGLT2) inhibitors. In this context, the objective of this work is to evaluate the benefits and limitations of SGLT2 inhibitors in the management of HF. The present study is an integrative literature review carried out from the PubMed and VHL databases. Seven randomized clinical studies controlled by placebo were analyzed, from which it was verified that SGLT2 inhibitors presented promising therapeutic effect, with cardioprotective and renoprotective action, in a broad spectrum of HF, reducing the risk of hospitalizations and deaths from causes cardiovascular effects, regardless of the presence or absence of DM2, in addition to being safe and well tolerated. Therefore, the use of SGLT2 inhibitors represents an additional effective and safe therapeutic alternative with the potential to modify the morbidity and mortality of HF.A pesar de las opciones terapéuticas actualmente disponibles para la Insuficiencia Cardíaca (IC), esta patología aún es responsable de altas tasas de morbilidad y mortalidad en la población. Ante estas limitaciones terapéuticas actuales, se justifica el desarrollo de estudios para evaluar la eficacia de nuevos fármacos en la IC, entre ellos los inhibidores del cotransportador sodio-glucosa tipo 2 (SGLT2). En este contexto, el objetivo de este trabajo es evaluar los beneficios y limitaciones de los inhibidores de SGLT2 en el manejo de la IC. El presente estudio es una revisión integrativa de la literatura realizada a partir de las bases de datos PubMed y BVS. Se analizaron siete estudios clínicos aleatorizados controlados con placebo, a partir de los cuales se verificó que los inhibidores de SGLT2 presentaron efecto terapéutico prometedor, con acción cardioprotectora y renoprotectora, en un amplio espectro de IC, reduciendo el riesgo de hospitalizaciones y muertes por causas efectos cardiovasculares, independientemente de la la presencia o ausencia de DM2, además de ser seguro y bien tolerado. Por lo tanto, el uso de inhibidores de SGLT2 representa una alternativa terapéutica adicional, eficaz y segura, con potencial para modificar la morbimortalidad de la IC.Apesar das opções terapêuticas atualmente disponíveis para a Insuficiência Cardíaca (IC), esta patologia ainda é responsável por altas taxas de morbimortalidade na população. Frente a essas limitações terapêuticas atuais, justifica-se o desenvolvimento de estudos para avaliarem a eficácia de novas drogas na IC, dentre estas os inibidores do cotransportador sódio-glicose do tipo 2 (SGLT2). Nesse contexto, o objetivo deste trabalho é avaliar os benefícios e as limitações dos inibidores SGLT2 no manejo da IC. O presente estudo trata-se de uma revisão integrativa da literatura realizada a partir das bases de dados PubMed e BVS. Analisou-se sete estudos clínicos randomizados controlados por placebo, a partir dos quais verificou-se que os inibidores SGLT2 apresentaram efeito terapêutico promissor, com ação cardioprotetora e renoprotetora, em um amplo espectro da IC, reduzindo o risco de hospitalizações e de mortes por causas cardiovasculares, independente da presença ou ausência de DM2, além de serem seguros e bem tolerados. Portanto, o uso dos Inibidores SGLT2 representa uma alternativa terapêutica adicional eficaz, segura e com potencial de modificar a morbimortalidade da IC.Research, Society and Development2023-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4050210.33448/rsd-v12i3.40502Research, Society and Development; Vol. 12 No. 3; e12412340502Research, Society and Development; Vol. 12 Núm. 3; e12412340502Research, Society and Development; v. 12 n. 3; e124123405022525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/40502/33108Copyright (c) 2023 Marcilyo Max Bezerra Soares; Arllen Mara Caminha Luz; Jefferson Noronha Bezerra Silva; Leonardo Francisco da Silva Guimarães; Daniel Matos de Sousa; Edvaldo Lucas da Costa Silva; Italo Rossi Roseno Martinshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSoares, Marcilyo Max Bezerra Luz, Arllen Mara Caminha Silva, Jefferson Noronha Bezerra Guimarães, Leonardo Francisco da Silva Sousa, Daniel Matos deSilva, Edvaldo Lucas da Costa Martins, Italo Rossi Roseno 2023-03-23T08:33:38Zoai:ojs.pkp.sfu.ca:article/40502Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2023-03-23T08:33:38Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option Avances en la farmacoterapia de la Insuficiencia Cardiaca: los Inhibidores del cotransportador sodio-glucosa tipo 2 (SGLT2) como opción terapéutica Avanços na farmacoterapia da Insuficiência Cardíaca: os Inibidores do cotransportador sódio-glicose do tipo 2 (SGLT2) como opção terapêutica |
title |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option |
spellingShingle |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option Soares, Marcilyo Max Bezerra Inibidores do Transportador 2 de Sódio-Glicose Insuficiência Cardíaca Eficácia. Sodium-Glucose Transporter 2 Inhibitors Heart Failure Efficacy. Inhibidores del transportador de sodio-glucosa 2 Insuficiencia cardíaca Eficacia. |
title_short |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option |
title_full |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option |
title_fullStr |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option |
title_full_unstemmed |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option |
title_sort |
Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option |
author |
Soares, Marcilyo Max Bezerra |
author_facet |
Soares, Marcilyo Max Bezerra Luz, Arllen Mara Caminha Silva, Jefferson Noronha Bezerra Guimarães, Leonardo Francisco da Silva Sousa, Daniel Matos de Silva, Edvaldo Lucas da Costa Martins, Italo Rossi Roseno |
author_role |
author |
author2 |
Luz, Arllen Mara Caminha Silva, Jefferson Noronha Bezerra Guimarães, Leonardo Francisco da Silva Sousa, Daniel Matos de Silva, Edvaldo Lucas da Costa Martins, Italo Rossi Roseno |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Soares, Marcilyo Max Bezerra Luz, Arllen Mara Caminha Silva, Jefferson Noronha Bezerra Guimarães, Leonardo Francisco da Silva Sousa, Daniel Matos de Silva, Edvaldo Lucas da Costa Martins, Italo Rossi Roseno |
dc.subject.por.fl_str_mv |
Inibidores do Transportador 2 de Sódio-Glicose Insuficiência Cardíaca Eficácia. Sodium-Glucose Transporter 2 Inhibitors Heart Failure Efficacy. Inhibidores del transportador de sodio-glucosa 2 Insuficiencia cardíaca Eficacia. |
topic |
Inibidores do Transportador 2 de Sódio-Glicose Insuficiência Cardíaca Eficácia. Sodium-Glucose Transporter 2 Inhibitors Heart Failure Efficacy. Inhibidores del transportador de sodio-glucosa 2 Insuficiencia cardíaca Eficacia. |
description |
Despite the therapeutic options currently available for Heart Failure (HF), this pathology is still responsible for high rates of morbidity and mortality in the population. Faced with these current therapeutic limitations, the development of studies to evaluate the effectiveness of new drugs in HF is justified, among them the sodium-glucose cotransporter type 2 (SGLT2) inhibitors. In this context, the objective of this work is to evaluate the benefits and limitations of SGLT2 inhibitors in the management of HF. The present study is an integrative literature review carried out from the PubMed and VHL databases. Seven randomized clinical studies controlled by placebo were analyzed, from which it was verified that SGLT2 inhibitors presented promising therapeutic effect, with cardioprotective and renoprotective action, in a broad spectrum of HF, reducing the risk of hospitalizations and deaths from causes cardiovascular effects, regardless of the presence or absence of DM2, in addition to being safe and well tolerated. Therefore, the use of SGLT2 inhibitors represents an additional effective and safe therapeutic alternative with the potential to modify the morbidity and mortality of HF. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/40502 10.33448/rsd-v12i3.40502 |
url |
https://rsdjournal.org/index.php/rsd/article/view/40502 |
identifier_str_mv |
10.33448/rsd-v12i3.40502 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/40502/33108 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 12 No. 3; e12412340502 Research, Society and Development; Vol. 12 Núm. 3; e12412340502 Research, Society and Development; v. 12 n. 3; e12412340502 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052619615633408 |